ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences

Core Insights - ImageneBio, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for immunological, autoimmune, and inflammatory diseases, with its lead asset being IMG-007, an anti-OX40 monoclonal antibody [1][3] Group 1: Company Overview - ImageneBio is dedicated to creating therapeutics with differentiated clinical profiles for patients suffering from immunological, autoimmune, and inflammatory diseases [3] - The company has completed Phase 1b/2a clinical trials of IMG-007 for atopic dermatitis and alopecia areata, and is currently conducting a Phase 2b clinical trial for moderate-to-severe atopic dermatitis [3] Group 2: Upcoming Events - Management will participate in the 2025 Stifel Healthcare Conference on November 13, 2025, at 9:20 am EST [2] - The company will also be present at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, at 10:00 am EST [2] - Live webcasts and archived recordings of these presentations will be available on the ImageneBio IR Site [2]